Switch theme
Sign up to access all valuation multiples
Nanologica AB is engaged in the production and sales of silica-based chromatography products. The company develops and manufactures nanoporous silica particles for life science applications. The company's drug delivery platforms are NLAB Spiro, NLAB Silica, and others, which focus on producing medicines for the benefit of patients. Its geographical segments are China, India, the United States, and the Rest of the world.
2004
15
LTM Revenue $3.0M
LTM EBITDA -$3.6M
$7.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nanologica has a last 12-month revenue (LTM) of $3.0M and a last 12-month EBITDA of -$3.6M.
In the most recent fiscal year, Nanologica achieved revenue of $1.5M and an EBITDA of -$4.7M.
Nanologica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nanologica valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0M | XXX | $1.5M | XXX | XXX | XXX |
| Gross Profit | -$38K | XXX | $0.4M | XXX | XXX | XXX |
| Gross Margin | -1% | XXX | 30% | XXX | XXX | XXX |
| EBITDA | -$3.6M | XXX | -$4.7M | XXX | XXX | XXX |
| EBITDA Margin | -120% | XXX | -311% | XXX | XXX | XXX |
| EBIT | -$5.3M | XXX | -$4.9M | XXX | XXX | XXX |
| EBIT Margin | -173% | XXX | -330% | XXX | XXX | XXX |
| Net Profit | -$5.7M | XXX | -$6.8M | XXX | XXX | XXX |
| Net Margin | -187% | XXX | -451% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nanologica's stock price is SEK 1 (or $0).
Nanologica has current market cap of SEK 97.6M (or $10.1M), and EV of SEK 76.5M (or $7.9M).
See Nanologica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.9M | $10.1M | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nanologica has market cap of $10.1M and EV of $7.9M.
Nanologica's trades at 5.3x EV/Revenue multiple, and -1.7x EV/EBITDA.
Equity research analysts estimate Nanologica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nanologica has a P/E ratio of -1.8x.
See valuation multiples for Nanologica and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10.1M | XXX | $10.1M | XXX | XXX | XXX |
| EV (current) | $7.9M | XXX | $7.9M | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 5.3x | XXX | XXX | XXX |
| EV/EBITDA | -2.2x | XXX | -1.7x | XXX | XXX | XXX |
| EV/EBIT | -1.5x | XXX | -1.6x | XXX | XXX | XXX |
| EV/Gross Profit | -205.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.8x | XXX | -1.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNanologica's last 12 month revenue growth is 158%
Nanologica's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.
Nanologica's rule of 40 is -3641% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nanologica's rule of X is 275% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nanologica and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 158% | XXX | 177% | XXX | XXX | XXX |
| EBITDA Margin | -120% | XXX | -311% | XXX | XXX | XXX |
| EBITDA Growth | -78% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -3641% | XXX | -153% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 275% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 359% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanologica acquired XXX companies to date.
Last acquisition by Nanologica was XXXXXXXX, XXXXX XXXXX XXXXXX . Nanologica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nanologica founded? | Nanologica was founded in 2004. |
| Where is Nanologica headquartered? | Nanologica is headquartered in Sweden. |
| How many employees does Nanologica have? | As of today, Nanologica has 15 employees. |
| Who is the CEO of Nanologica? | Nanologica's CEO is Mr. Andreas Bhagwani. |
| Is Nanologica publicy listed? | Yes, Nanologica is a public company listed on STO. |
| What is the stock symbol of Nanologica? | Nanologica trades under NICA ticker. |
| When did Nanologica go public? | Nanologica went public in 2015. |
| Who are competitors of Nanologica? | Similar companies to Nanologica include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nanologica? | Nanologica's current market cap is $10.1M |
| What is the current revenue of Nanologica? | Nanologica's last 12 months revenue is $3.0M. |
| What is the current revenue growth of Nanologica? | Nanologica revenue growth (NTM/LTM) is 158%. |
| What is the current EV/Revenue multiple of Nanologica? | Current revenue multiple of Nanologica is 2.6x. |
| Is Nanologica profitable? | Yes, Nanologica is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nanologica? | Nanologica's last 12 months EBITDA is -$3.6M. |
| What is Nanologica's EBITDA margin? | Nanologica's last 12 months EBITDA margin is -120%. |
| What is the current EV/EBITDA multiple of Nanologica? | Current EBITDA multiple of Nanologica is -2.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
